Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

In this study, researchers found that inhibiting inducible nitric oxide synthase (iNOS) promoted hair growth in diabetic mice, suggesting iNOS-derived nitric oxide contributes to hair loss under diabetic inflammatory conditions.

This review discusses the biological and cosmetic aspects of hair aging and reports no new clinical results; it highlights current treatments and future research directions to address both aging factors.

This review discusses the classification, diagnosis, and potential treatment pathways for Alopecia Areata, emphasizing the complex genetic and immunological factors involved, but reports no new clinical results.

This study found that although both adults and adolescents with alopecia areata experience a significant quality of life impact from ≥50% scalp hair loss, the impact is greater for adolescents, as indicated by their higher Dermatology Life Quality Index scores.

This study found that Janus Kinase inhibitors, tofacitinib and baricitinib, showed effectiveness and safety in treating severe alopecia areata in a real-world setting, with optimal tolerability noted in younger individuals.

This review discusses the role of Janus-kinase inhibitors in treating severe atopic dermatitis and alopecia areata, presenting case studies that show their efficacy and calling for further research on long-term effectiveness and safety.

This study describes the positive effects of the JAK inhibitor ruxolitinib in treating autoimmune manifestations in three patients with autoimmune polyendocrine syndrome type-1 over a period of at least 30 months, with excellent tolerance and no adverse events observed.

This review suggests that the gut microbiome and metabolome may play a significant role in alopecia areata and emphasizes the potential of targeting these factors for improved prevention, diagnosis, and treatment strategies for this skin condition.

In this study, researchers used Mendelian randomization to find a significant genetic association between rheumatoid arthritis and an increased risk of alopecia areata, suggesting RA patients should be vigilant for potential AA development.

This case report presents the first successful treatment of perifolliculitis capitis abscedens et suffodiens using a regimen of adalimumab and baricitinib, resulting in almost complete healing after nine months.

This review examined the role, efficacy, and safety of Janus kinase inhibitors in treating alopecia areata, noting that baricitinib has received approval as the first on-label treatment due to positive outcomes in multiple trials.

This review discusses the mechanisms of hair repigmentation and reports no clinical results; the authors suggest further research into topical treatments for reversing gray hair.

In laboratory experiments, this study found that the topical prodrug SCD-153, a derivative of 4-methyl itaconate, reduced inflammation-related gene expression and induced significant hair growth in mice, suggesting it as a promising treatment candidate for alopecia areata.

In this study, two patients with alopecia universalis continued using tofacitinib during active COVID-19 infection and showed no worsening of their illness, despite potential concerns about immunosuppression.

This study found that skin surface lipids contain measurable mRNAs, providing a non-invasive way to study skin diseases, with specific gene expression changes observed in atopic dermatitis patients.

This review examines the role of IL-15 in alopecia areata treatment but reports no clinical results, as there are currently insufficient studies to determine its therapeutic potential.

This review discusses recent advances in the treatment of alopecia areata, highlighting new potential therapies like JAK inhibitors and PRP, and reports no new clinical results.

In this study, researchers developed a predictive model for the onset of alopecia areata by analyzing six datasets to identify key feature genes and employing various machine learning algorithms, ultimately finding the XGBoost model most effective for clinical application.

In this case report, a 30-year-old male with alopecia universalis and autoimmune conditions experienced treatment failure with JAK inhibitors, including ritlecitinib, and developed severe musculoskeletal pain, indicating a potential novel adverse effect that warrants further pharmacovigilance.

In this study on testosterone-induced benign prostatic hyperplasia in rats, hydroxychloroquine significantly reduced prostate-related markers and enhanced therapeutic effects when combined with finasteride, suggesting potential as a new treatment approach.

In this review, researchers explored the multifaceted role of NF-κB signaling in various biological processes and diseases, including its interactions with other pathways, and discussed possible therapeutic approaches targeting this pathway for treating conditions like cancer, autoimmune disorders, and COVID-19.

This source reports that based on international Phase 3 trial results, the JAK1/2 inhibitor baricitinib was approved in Japan in June 2022 for treating extensive alopecia areata, offering a potentially useful treatment option.

This paper reviews current and developing treatments for severe alopecia areata but reports no new clinical findings; the authors highlight the need for standardized treatment protocols.

This review explores the promising but varied effectiveness of tyrosine kinase inhibitors for treating different skin diseases, indicating their potential in dermatology while acknowledging the need for more evidence.

This article reviews the role of the JAK-STAT pathway in inflammatory skin diseases and considers the therapeutic benefits of JAK inhibitors, presenting them as promising treatments but reports no new experimental results.

This Cochrane Review protocol aims to evaluate the effectiveness and safety of various treatments for alopecia areata through a network meta-analysis, but no specific study findings are reported yet.

This study reports that a novel gain-of-function mutation in TMEM173, combined with polymorphisms in TMEM173 and IFIH1, results in a distinct clinical phenotype with features of SAVI, including alopecia and photosensitivity.

This chapter reviews signaling pathways related to androgenic alopecia in dermal papilla cells of balding human scalps, integrating published information and analysis of molecular interactions, without reporting new clinical results.

This review discusses recent advances in understanding alopecia areata's disease mechanisms and highlights JAK molecules as promising therapeutic targets, but reports no new clinical results; controlled trials are needed.

This review synthesizes both traditional and emerging molecular mechanisms of tissue remodeling across different organs, aiming to establish a theoretical basis for precision interventions in pathological conditions, according to the authors.